Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
Vancheswaran Gopalakrishnan(The University of Texas MD Anderson Cancer Center), C. N. Spencer(The University of Texas MD Anderson Cancer Center), Luigi Nezi(The University of Texas MD Anderson Cancer Center), Alexandre Reuben(The University of Texas MD Anderson Cancer Center), Miles C. Andrews(The University of Texas MD Anderson Cancer Center), Tatiana V. Karpinets(The University of Texas MD Anderson Cancer Center), Peter A. Prieto(The University of Texas MD Anderson Cancer Center), Diego Vicente(The University of Texas MD Anderson Cancer Center), Kristi L. Hoffman(The University of Texas MD Anderson Cancer Center), Spencer C. Wei(The University of Texas MD Anderson Cancer Center), Alexandria P. Cogdill(The University of Texas MD Anderson Cancer Center), L. Zhao(The University of Texas MD Anderson Cancer Center), Courtney W. Hudgens(The University of Texas MD Anderson Cancer Center), Diane S. Hutchinson(Baylor College of Medicine), Teresa Manzo(The University of Texas MD Anderson Cancer Center), Mariana Petaccia de Macêdo(The University of Texas MD Anderson Cancer Center), Tiziana Cotechini(Oregon Health & Science University), Tapsi Kumar(The University of Texas MD Anderson Cancer Center), W. S. Chen(The University of Texas MD Anderson Cancer Center), Sangeetha M. Reddy(The University of Texas MD Anderson Cancer Center), Robert Szczepaniak‐Sloane(The University of Texas MD Anderson Cancer Center), Jessica Galloway-Peña(The University of Texas MD Anderson Cancer Center), Hong Jiang(The University of Texas MD Anderson Cancer Center), P. L. Chen(The University of Texas MD Anderson Cancer Center), Elizabeth J. Shpall(The University of Texas MD Anderson Cancer Center), Katayoun Rezvani(The University of Texas MD Anderson Cancer Center), Amin M. Alousi(The University of Texas MD Anderson Cancer Center), Roy F. Chemaly(The University of Texas MD Anderson Cancer Center), Samuel A. Shelburne(The University of Texas MD Anderson Cancer Center), Luis M. Vence(The University of Texas MD Anderson Cancer Center), Pablo C. Okhuysen(The University of Texas MD Anderson Cancer Center), V. Behrana Jensen(The University of Texas MD Anderson Cancer Center), Alton G. Swennes(Baylor College of Medicine), Florencia McAllister(The University of Texas MD Anderson Cancer Center), Erick Riquelme(The University of Texas MD Anderson Cancer Center), Yexi Zhang(The University of Texas MD Anderson Cancer Center), Emmanuelle Le Chatelier(Département Génétique Animale), Laurence Zitvogel(Institut Gustave Roussy), Nicolas Pons(Département Génétique Animale), Jacob L. Austin-Breneman(The University of Texas MD Anderson Cancer Center), Lauren E. Haydu(The University of Texas MD Anderson Cancer Center), Elizabeth M. Burton(The University of Texas MD Anderson Cancer Center), Julie M. Gardner(The University of Texas MD Anderson Cancer Center), Elizabeth Sirmans(The University of Texas MD Anderson Cancer Center), Jiemiao Hu(The University of Texas MD Anderson Cancer Center), Alexander J. Lazar(The University of Texas MD Anderson Cancer Center), Takahiro Tsujikawa(Oregon Health & Science University), Adi Diab(The University of Texas MD Anderson Cancer Center), Hussein A. Tawbi(The University of Texas MD Anderson Cancer Center), Isabella C. Glitza(The University of Texas MD Anderson Cancer Center), Wen-Jen Hwu(The University of Texas MD Anderson Cancer Center), Sapna P. Patel(The University of Texas MD Anderson Cancer Center), Scott E. Woodman(The University of Texas MD Anderson Cancer Center), Rodabe N. Amaria(The University of Texas MD Anderson Cancer Center), Michael A. Davies(The University of Texas MD Anderson Cancer Center), Jeffrey E. Gershenwald(The University of Texas MD Anderson Cancer Center), Patrick Hwu(The University of Texas MD Anderson Cancer Center), J. E. Lee(The University of Texas MD Anderson Cancer Center), J. Zhang(The University of Texas MD Anderson Cancer Center), Lisa M. Coussens(Oregon Health & Science University), Zachary A. Cooper(The University of Texas MD Anderson Cancer Center), P. Andrew Futreal(The University of Texas MD Anderson Cancer Center), Carrie R. Daniel(The University of Texas MD Anderson Cancer Center), Nadim J. Ajami(Baylor College of Medicine), Joseph F. Petrosino(Baylor College of Medicine), Michael T. Tetzlaff(The University of Texas MD Anderson Cancer Center), Padmanee Sharma(The University of Texas MD Anderson Cancer Center), James P. Allison(The University of Texas MD Anderson Cancer Center), Robert R. Jenq(The University of Texas MD Anderson Cancer Center), Jennifer A. Wargo(The University of Texas MD Anderson Cancer Center)
Cited by 4,635Open Access
Abstract
Good bacteria help fight cancer Resident gut bacteria can affect patient responses to cancer immunotherapy (see the Perspective by Jobin). Routy et al. show that antibiotic consumption is associated with poor response to immunotherapeutic PD-1 blockade. They profiled samples from patients with lung and kidney cancers and found that nonresponding patients had low levels of the bacterium Akkermansia muciniphila . Oral supplementation of the bacteria to antibiotic-treated mice restored the response to immunotherapy. Matson et al. and Gopalakrishnan et al. studied melanoma patients receiving PD-1 blockade and found a greater abundance of “good” bacteria in the guts of responding patients. Nonresponders had an imbalance in gut flora composition, which correlated with impaired immune cell activity. Thus, maintaining healthy gut flora could help patients combat cancer. Science , this issue p. 91 , p. 104 , p. 97 ; see also p. 32
Related Papers
Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB
Todd Z. DeSantis, Philip Hugenholtz, N. Larsen et al.|Applied and Environmental Microbiology|2006|11.2k